Shares of UnitedHealth (UNH) tumbled over 5% during Monday’s premarket session, falling to approximately $380.35, following Berkshire Hathaway’s disclosure that it had liquidated its complete ownership stake in the healthcare giant.
UnitedHealth Group Incorporated, UNH
The conglomerate’s most recent 13F regulatory filing, which reflects investment positions through March 31, revealed that Berkshire divested its entire holding of roughly 5 million shares in UNH. The exit is particularly striking given that Berkshire had only initiated the position during the second quarter of 2025 — representing a holding period of less than twelve months.
This strategic shift represents part of a comprehensive portfolio realignment orchestrated by Greg Abel, who assumed the chief executive role at Berkshire on January 1, taking the helm from legendary investor Warren Buffett.
When an investor of Berkshire’s caliber exits a position so rapidly, market participants pay attention. The disclosure triggered a wave of selling as investors interpreted the move as a bearish signal.
Berkshire’s divestment activity extended beyond UNH. The investment powerhouse also completely liquidated holdings in Amazon, Domino’s, Pool Corp, Mastercard, and Visa throughout the first quarter. These stocks experienced modest declines in early Monday trading.
Meanwhile, Berkshire initiated new positions in Delta Air Lines and Macy’s, while expanding existing stakes in Alphabet and the New York Times.
The selling pressure extends beyond the Berkshire announcement. UNH faces mounting pressure from a federal government moratorium that blocks new Medicare enrollments for home healthcare service providers, introducing significant regulatory uncertainty.
Compounding these challenges, company leadership has announced intentions to slash 1.3 million members from its Medicare Advantage programs. This aggressive reduction represents a calculated approach to preserve profitability in an environment of accelerating medical expense inflation.
The convergence of these factors — a prominent institutional investor exit, mounting regulatory obstacles, and intentional membership contraction — has prompted market participants to recalibrate their expectations for the stock’s near-term trajectory.
UNH continues to operate under Department of Justice scrutiny related to its billing methodologies, an investigation that has lingered for an extended period. This regulatory cloud continues to cast a shadow over the company’s prospects.
Heading into this week, the stock had already declined approximately 20% year-to-date, making Monday’s selloff another difficult development in what has been a challenging period for the managed-care leader.
However, the picture isn’t entirely bleak. UnitedHealth’s first-quarter financial performance demonstrated operational resilience.
The company surpassed Wall Street’s Q1 profit projections and elevated its full-year earnings forecast, developments that had offered some support to the stock before Monday’s Berkshire disclosure.
Technical indicators currently signal a Buy rating for UNH, with average daily trading volume hovering around 8.49 million shares. The company maintains a market capitalization of roughly $357.7 billion.
For the immediate future, the stock faces the challenge of digesting Berkshire’s high-profile exit alongside ongoing concerns surrounding Medicare reimbursement pressures and enrollment dynamics.
The post UnitedHealth (UNH) Stock Plunges 5% as Berkshire Hathaway Dumps Entire Position appeared first on Blockonomi.

